Loading…

Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction

OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical,...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes spectrum 2020-11, Vol.33 (4), p.299-306
Main Authors: Jayakumari, Chellamma, Jabbar, Puthiyaveettil Khadar, Soumya, Sarayu, Jayakumar, R.V., Das, Darvin Vamadevan, Girivishnu, Gopi, Gopi, Anjana, Gomez, Ramesh, Sreenath, Ravindranath, Nair, Abilash
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83
cites cdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83
container_end_page 306
container_issue 4
container_start_page 299
container_title Diabetes spectrum
container_volume 33
creator Jayakumari, Chellamma
Jabbar, Puthiyaveettil Khadar
Soumya, Sarayu
Jayakumar, R.V.
Das, Darvin Vamadevan
Girivishnu, Gopi
Gopi, Anjana
Gomez, Ramesh
Sreenath, Ravindranath
Nair, Abilash
description OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.
doi_str_mv 10.2337/ds19-0046
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7666608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2464865040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</originalsourceid><addsrcrecordid>eNpdkU1LJDEQhoMo6qoH_0HAi3voNV-dTO9hQUZ3FQYUHfEYMknFifZ0ZpNuQX-9aRRB65BKJU9eqvIidEjJL8a5OnGZNhUhQm6gXdoIUSle882yJ4JUDZX1DvqR8yMhhFHGttEO54xxJdUuep2FdXD4OkUfWsChw5edC6bD16YP0PUZ34d-iecva8AMnwWzgB7ybzxfAr61sZz6mPBpv4QUs23L2geLpya5EJ9NtkNrUnmWwWTANyE_4Rtwg-1D7PbRljdthoOPvIfu_p7PpxfV7Orf5fR0VlnW1LISglLfeEoJEEe5rb30XBIlvLOOEDUxBkrJnVwslBA1V8w2paydMNy5Cd9Df95118NiBc6WqZJp9TqFlUkvOpqgv950Yakf4rNWsgQZBY4_BFL8P0Du9SpkC21rOohD1kzI0hDlTV3Qo2_oYxxSV8YbKTGRdbGkUD_fKVs-LSfwn81QokdH9eioHh3lbwP7kjI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2464865040</pqid></control><display><type>article</type><title>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</title><source>PubMed Central</source><creator>Jayakumari, Chellamma ; Jabbar, Puthiyaveettil Khadar ; Soumya, Sarayu ; Jayakumar, R.V. ; Das, Darvin Vamadevan ; Girivishnu, Gopi ; Gopi, Anjana ; Gomez, Ramesh ; Sreenath, Ravindranath ; Nair, Abilash</creator><creatorcontrib>Jayakumari, Chellamma ; Jabbar, Puthiyaveettil Khadar ; Soumya, Sarayu ; Jayakumar, R.V. ; Das, Darvin Vamadevan ; Girivishnu, Gopi ; Gopi, Anjana ; Gomez, Ramesh ; Sreenath, Ravindranath ; Nair, Abilash</creatorcontrib><description>OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.</description><identifier>ISSN: 1040-9165</identifier><identifier>EISSN: 1944-7353</identifier><identifier>DOI: 10.2337/ds19-0046</identifier><identifier>PMID: 33223767</identifier><language>eng</language><publisher>Alexandria: American Diabetes Association</publisher><subject>Arteriosclerosis ; Atherosclerosis ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Dyslipidemia ; High density lipoprotein ; Hyperlipidemia ; Lipids ; Low density lipoprotein ; Metabolic disorders ; Patients ; Statins ; Thyroid</subject><ispartof>Diabetes spectrum, 2020-11, Vol.33 (4), p.299-306</ispartof><rights>Copyright American Diabetes Association Nov 1, 2020</rights><rights>2020 by the American Diabetes Association 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</citedby><cites>FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</cites><orcidid>0000-0001-6776-1582</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666608/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666608/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Jayakumari, Chellamma</creatorcontrib><creatorcontrib>Jabbar, Puthiyaveettil Khadar</creatorcontrib><creatorcontrib>Soumya, Sarayu</creatorcontrib><creatorcontrib>Jayakumar, R.V.</creatorcontrib><creatorcontrib>Das, Darvin Vamadevan</creatorcontrib><creatorcontrib>Girivishnu, Gopi</creatorcontrib><creatorcontrib>Gopi, Anjana</creatorcontrib><creatorcontrib>Gomez, Ramesh</creatorcontrib><creatorcontrib>Sreenath, Ravindranath</creatorcontrib><creatorcontrib>Nair, Abilash</creatorcontrib><title>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</title><title>Diabetes spectrum</title><description>OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.</description><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Dyslipidemia</subject><subject>High density lipoprotein</subject><subject>Hyperlipidemia</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Metabolic disorders</subject><subject>Patients</subject><subject>Statins</subject><subject>Thyroid</subject><issn>1040-9165</issn><issn>1944-7353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkU1LJDEQhoMo6qoH_0HAi3voNV-dTO9hQUZ3FQYUHfEYMknFifZ0ZpNuQX-9aRRB65BKJU9eqvIidEjJL8a5OnGZNhUhQm6gXdoIUSle882yJ4JUDZX1DvqR8yMhhFHGttEO54xxJdUuep2FdXD4OkUfWsChw5edC6bD16YP0PUZ34d-iecva8AMnwWzgB7ybzxfAr61sZz6mPBpv4QUs23L2geLpya5EJ9NtkNrUnmWwWTANyE_4Rtwg-1D7PbRljdthoOPvIfu_p7PpxfV7Orf5fR0VlnW1LISglLfeEoJEEe5rb30XBIlvLOOEDUxBkrJnVwslBA1V8w2paydMNy5Cd9Df95118NiBc6WqZJp9TqFlUkvOpqgv950Yakf4rNWsgQZBY4_BFL8P0Du9SpkC21rOohD1kzI0hDlTV3Qo2_oYxxSV8YbKTGRdbGkUD_fKVs-LSfwn81QokdH9eioHh3lbwP7kjI</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Jayakumari, Chellamma</creator><creator>Jabbar, Puthiyaveettil Khadar</creator><creator>Soumya, Sarayu</creator><creator>Jayakumar, R.V.</creator><creator>Das, Darvin Vamadevan</creator><creator>Girivishnu, Gopi</creator><creator>Gopi, Anjana</creator><creator>Gomez, Ramesh</creator><creator>Sreenath, Ravindranath</creator><creator>Nair, Abilash</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6776-1582</orcidid></search><sort><creationdate>20201101</creationdate><title>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</title><author>Jayakumari, Chellamma ; Jabbar, Puthiyaveettil Khadar ; Soumya, Sarayu ; Jayakumar, R.V. ; Das, Darvin Vamadevan ; Girivishnu, Gopi ; Gopi, Anjana ; Gomez, Ramesh ; Sreenath, Ravindranath ; Nair, Abilash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Dyslipidemia</topic><topic>High density lipoprotein</topic><topic>Hyperlipidemia</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Metabolic disorders</topic><topic>Patients</topic><topic>Statins</topic><topic>Thyroid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jayakumari, Chellamma</creatorcontrib><creatorcontrib>Jabbar, Puthiyaveettil Khadar</creatorcontrib><creatorcontrib>Soumya, Sarayu</creatorcontrib><creatorcontrib>Jayakumar, R.V.</creatorcontrib><creatorcontrib>Das, Darvin Vamadevan</creatorcontrib><creatorcontrib>Girivishnu, Gopi</creatorcontrib><creatorcontrib>Gopi, Anjana</creatorcontrib><creatorcontrib>Gomez, Ramesh</creatorcontrib><creatorcontrib>Sreenath, Ravindranath</creatorcontrib><creatorcontrib>Nair, Abilash</creatorcontrib><collection>CrossRef</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes spectrum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jayakumari, Chellamma</au><au>Jabbar, Puthiyaveettil Khadar</au><au>Soumya, Sarayu</au><au>Jayakumar, R.V.</au><au>Das, Darvin Vamadevan</au><au>Girivishnu, Gopi</au><au>Gopi, Anjana</au><au>Gomez, Ramesh</au><au>Sreenath, Ravindranath</au><au>Nair, Abilash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</atitle><jtitle>Diabetes spectrum</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>33</volume><issue>4</issue><spage>299</spage><epage>306</epage><pages>299-306</pages><issn>1040-9165</issn><eissn>1944-7353</eissn><abstract>OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.</abstract><cop>Alexandria</cop><pub>American Diabetes Association</pub><pmid>33223767</pmid><doi>10.2337/ds19-0046</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6776-1582</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1040-9165
ispartof Diabetes spectrum, 2020-11, Vol.33 (4), p.299-306
issn 1040-9165
1944-7353
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7666608
source PubMed Central
subjects Arteriosclerosis
Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Diabetes
Diabetes mellitus (non-insulin dependent)
Dyslipidemia
High density lipoprotein
Hyperlipidemia
Lipids
Low density lipoprotein
Metabolic disorders
Patients
Statins
Thyroid
title Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A55%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20Profile%20in%20Indian%20Patients%20With%20Type%202%20Diabetes:%20The%20Scope%20for%20Atherosclerotic%20Cardiovascular%20Disease%20Risk%20Reduction&rft.jtitle=Diabetes%20spectrum&rft.au=Jayakumari,%20Chellamma&rft.date=2020-11-01&rft.volume=33&rft.issue=4&rft.spage=299&rft.epage=306&rft.pages=299-306&rft.issn=1040-9165&rft.eissn=1944-7353&rft_id=info:doi/10.2337/ds19-0046&rft_dat=%3Cproquest_pubme%3E2464865040%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2464865040&rft_id=info:pmid/33223767&rfr_iscdi=true